This study is testing a new cell therapy called huCART19-IL18-eDHFR cells for people with follicular lymphoma that has come back or not responded to at least two previous treatments. These cells are your own immune cells (T cells) that have been specially modified to fight cancer. Researchers want to see if this treatment is safe, how well it works, and how it moves through the body using a special imaging agent called [18F]Fluoropropyl-Trimethoprim (a drug that helps visualize the cells). The study is looking for 6 participants aged 18 or older who have follicular lymphoma grades 1-3A and have already received certain prior therapies, including an anti-CD20 antibody and an alkylating agent.

Study design

This is a Phase 1, open-label study, meaning both you and your doctors will know what treatment you are receiving. It will involve a small group of 6 participants and will start with one treatment group.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will track changes in tumor uptake using PET/CT imaging for up to 6 months after receiving the huCART19-IL18-eDHFR cells.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.